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for invasive fungal infection can ensure use of pre emptive therapy
in selected cases. Better diagnostic modalities including radiology
like high resolution computed tomogramsof the chest, earlier inva-
sive procedures including bronchoscopy and biopsy coupled with
serological studies like beta d-glucan, and galactomannan have
shortened the time to diagnosis of fungal infections. Simultane-
ously, advances in fungal identiﬁcation, both culture andmolecular
techniques have helped the clinician use themost appropriate anti-
fungal agent.We also have an expanding armamentarium of drugs,
both new drugs in existing classes and a new class of antifungal
agents, to best suit the individual patient. There is still scope for
signiﬁcant improvement in areas, which include evaluation of new
markers which could hasten time to diagnosis, and new agents
which can tackle some of the more difﬁcult or resistant fungi.
http://dx.doi.org/10.1016/j.ijid.2016.02.151
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Neutropenic sepsis
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Abstract: Chemotherapy-induced neutropenia is the leading
cause for bacterial and fungal infections in patients with haema-
tological malignancies. The drop of neutrophyls count below 1000
cells/cmm increase the risk of febrile episodes (TC>38 ◦C) and
infectious complications but most of the bacteremic episodes are
documented when neutrophils count is below 100/cmm (severe
neutropenia). The duration of neutropenia also play a pivotal role in
determining the risk of infection: prolonged neutropenia is deﬁned
by a duration of 3 weeks. Among 100 febrile episodes occurring
during neutropenia 40% are FUO, 20% are clinically documented,
20% are microbiologically documented and 20% are bacteremia.
Gram-positive cocci (CNS, St. aureus, streptococci, enterococci)
represent around 50% of the blood isolates and gram-negative
bacilli (Ps. aeruginosa, enterobacteriaceae) are documented in the
same rate. Recently, an increasing rate of MDR gram-negative
bacilli (i.e. K.pneumoniae KPC-producing and other carbapenem-
resistant gram-negative bugs) are responsible for local epidemic
clusters. Empiric antibiotic therapy is recommended in patient
with febrile neutropenia: blood cultures (at least 2 sets) should
be taken immediately and therapy started in 1 hour (febrile
neutropenia is a medical emergency). Monotherapy with a beta-
lactam antibiotic with anti-pseudomonal activity (meropenem,
piperacillin/tazobactam) is usually started, adding an anti gram-
positive agent (vancomycin, daptomycin) in case of a documented
gram-positive bacteremia or in patientwith local sign of CVC infec-
tion (“escalation” strategy). A de-escalation strategy is preferred
in patient presenting with severe sepsis or septic shock and in
the setting of a cluster of MDR gram-negative bacilli. Combination
therapy is started (betalactam, aminoglycoside, antistaphylococcal
agent) then de-escalated on the basis of microbiological docu-
mentation and/or clinical response. In case of KPC-producing K.
pneumoniae epidemic a combination of colistin, tygecicline and
gentamicin should be considered; some clinicians suggest the use
of high-dose meropenem (although many of the isolates shows a
MIC >128 mg/l). It is noteworthy that the use of rectal swab to
identify colonized patients may be important for the infection con-
trol procedures (patient isolation) and to predict the subsequent
sepsis. In neutropenic patients with fever not responding to 3 or 4
days of antibiotic therapy the start of an empiric antifungal therapy
(echinocandin, amphotericin B) should be considered. Serological
markers (betaglucan, mannan/anti-mannan etc.) may be useful to
select patients at higher risk of yeast infection; galactomannan is
otherwise useful to suspect Aspergillus infection.
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Infectious complications of biologic
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Abstract: An expanding array of new biologics are entering
clinical practice to supplement existing therapies in the man-
agement of neoplastic diseases, organ transplantation, rheumatic
diseases and numerous other inﬂammatory disease states. These
biologics include monoclonal antibodies, soluble cytokine recep-
tor constructs, growth factors and recombinant proteins. Their
use have revolutionized treatment for some severe forms of
rheumatoid arthritis, multiple sclerosis (MS) and inﬂammatory
bowel disease where biologics have now become the stan-
dard of care. Such agents are not without risk as a number
of common infections and at times rather unusual infections
are being recognized with increasing frequency following the
institution of biologics. Opportunistic infections are particu-
larly a concern in patients receiving combination therapy with
multiple biologics in addition to standard immunosuppressive
agents such as corticosteroids, anti-metabolites and calcineurin
inhibitors.
Because of their frequency and severity, the infections of great-
est importance following a biologic are tuberculosis, opportunistic
and endemic mycoses (histoplasmosis and coccidioidomycosis),
and high risk viral infections (HIV, hepatitis B and C, adenoviruses
and the JC virus that causes progressive multifocal leukoen-
cephalopathy (PML). While these infections should receive the
most attention, an array of pathogens ranging from viruses (herpes
viruses, paramyxoviruses), bacteria (e.g. listeriosis, mycobacterial
infections, skin and soft tissue pathogens, respiratory infections),
numerous opportunistic fungi, and parasitic organisms including
toxoplasmosis, pneumocystosis, and strongyloidiasis should also
be considered. The greater the intensity, duration and combina-
tions of biologics all increase the risk of secondary infection. Many
biologics have prolonged immunosuppressive effects, thereby
limiting cost and improving convenience, but this long pharma-
codynamic effect leads to infection risk for prolonged periods
up to years after stopping the treatment. A number of these
infections can be detected in latent forms allowing for pro-
phylaxis or avoidance of some biologics such as screening for
PML by serology before using natalizumab (alpha-4 integrin
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monoclonal antibody), or screening for latent TB before using TNF
inhibitors.
http://dx.doi.org/10.1016/j.ijid.2016.02.153
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Cytomegalovirus
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Abstract: Cytomegalovirus (CMV) remains an important
pathogen in transplant patients. Sensitive and rapid turnaround
quantitative PCR based monitoring coupled with the availability of
effective antiviral therapy has reduced the overall burden of CMV
disease after transplantation. However, in hematopoietic stem cell
transplant (HSCT) patients, the increasing use of new donor and
stem cell sources present new challenges in the prevention and
treatment of CMV. Gastrointestinal disease is now the most com-
monend-organmanifestationofCMVinfectionafterHSCT,whereas
pneumonia remains associated with high mortality. In addition,
indirect effects of CMV infection continue to have both positive
and negative effects on outcomes after HSCT. Antivirals with novel
mechanisms of action and improved toxicity proﬁles compared to
those currently available are in late phase clinical trials. Also CMV
vaccines are in development. Despite these advances, CMV is likely
to remain a signiﬁcant pathogen in transplant recipients.
http://dx.doi.org/10.1016/j.ijid.2016.02.154
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New antibiotics: What do we need?
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Abstract: Lack of effective antimicrobial therapy for multidrug-
resistant organisms (MDROs) has been a growing concern
particularly due to spread of extended-spectrum beta lactamase
(ESBL) and carbapenem resistant Enteriobacteriaceae (CRE). Better
therapeutics for MDROs are needed.
Common MDROs include methicillin-resistant Staphylococcus
aureus (MRSA), vancomycin-resistant Enterococcus (VRE), ESBL
and CRE. Gram-positive organisms such as MRSA and VRE are sta-
ble or declining in frequency while gram-negative ESBLs and CREs
are increasing. Recent antibiotics generally focus on MRSA and
gram-positiveMDROswith few new agents effective against gram-
negative organisms. Outside of common healthcare-associated
MDROs, Gonococcus has become highly antibiotic-resistant in
many parts of the world. Furthermore, most therapy for MDROs
is intravenous and associated with a high rate of adverse effects
and burden of disease related to long courses of treatment.
New antibiotics are needed with novel mechanisms of action
against MDRO organisms, fewer side effects, less impact on the
microbiome and easier, non intravenous delivery. Studies of new
drugs need to focus on rational use with minimal duration, easiest
formof delivery and clear recognition of effects on themicrobiome.
Use of new antibiotics must be appropriate and avoid overuse.
ChoosingWisely and the growth of Antimicrobial Stewardshipmay
help appropriate use.
Finally, a new model of infectious disease management is
developing based around the microbiome. Manipulation of the
microbiome may become a mainstay for treatment of many dis-
eases. Currently, fecal transplants for C. difﬁcile are the only
approach to microbiome manipulation proven to work. Other uses
may include decolonization of MDROs from the gastrointestinal
track. Future microbiome manipulations may include targeted
microbiome changes via capsules to the GI tract and possible inoc-
ulations to the skin or mucosal surfaces. Development of ways to
manipulate the microbiome could improve treatment of infectious
disease without producing antibiotic resistance.
Development of antimicrobials active against ESBLs, and CRES
that are safe and easy to use is needed. Longer range antimicrobial
therapies will likely involve microbiome manipulation.
http://dx.doi.org/10.1016/j.ijid.2016.02.155
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The antibiotic pipeline: What can we expect?
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Abstract: Antibiotic resistance is widespread. Despite the rec-
ognized and growing need for new antibiotics, today most large
pharmaceutical companies have dropped active antibacterial drug
discovery programmes. While antibiotics are regarded as non-
proﬁtable compared to other ﬁelds, small companies—mostly
backedbypromising academicdiscoveries—are stepping in todrive
research and early clinical development in the antibiotics ﬁeld. In
the 1980s and 90s the antibiotic pipelines were satisfying the need
for improved antibiotics against the prevalent resistant strains at
that time. Currently, extensively- or pan-resistant Gram-negative
bacteria require novel antibiotics without co- and cross-resistance
to known drug classes. A few research&development programs
based on classical antibacterial compounds against Gram-negative
bacteria that bind to new targets or have a new mode of action
are in the early research phase and their potential is difﬁcult
to assess. Due to such thin discovery pipelines, attitudes have
changed and antibacterial approaches outside the mainstream
are increasingly pursued and publicly funded. These alterna-
tive methodologies range from peptides and peptidomimetics
to antibodies, prophylactic and therapeutic vaccines, adjunctive
